JAZZ Q3 2018 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$469M+14.0% YoY

Gross Profit

$443M94.3% margin

Operating Income

$189M40.2% margin

Net Income

$149M31.8% margin

EPS (Diluted)

$2.41

QoQ Revenue Growth

-6.2%

Cash Flow

Operating Cash Flow

$221M

Free Cash Flow

$217M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$5.5B

Total Liabilities

$2.5B

Stockholders' Equity

$3.0B

Cash & Equivalents

$499M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$469M	$412M	+14.0%
Gross Profit	$443M	$381M	+16.3%
Operating Income	$189M	$86M	+118.4%
Net Income	$149M	$64M	+135.0%

Revenue Segments

Product And Services, Product Sales

$465M50%

Xyrem

$357M38%

Erwinaze And Erwinase

$41M4%

Defitelio/Defibrotide

$36M4%

Vyxeos

$21M2%

Prialt

$6M1%

Product And Services, Royalties And Contract Revenue

$4M0%

Other Products

$4M0%

Geographic Segments

UNITED STATES

$430M92%

Europe

$31M7%

Other Countries

$9M2%